Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
Posted: February 13, 2025 at 2:44 am
Basel, 12 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam) tablet for people living with spinal muscular atrophy (SMA). Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water.
Read the original post:
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
Posted in Global News Feed
Comments Off on FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
Mdxhealth to Present Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on February 26
Posted: February 13, 2025 at 2:44 am
Company to Host Conference Call with Live Q&A, February 26, 2025, at 4:30pm ET / 22:30 CET
See the original post:
Mdxhealth to Present Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on February 26
Posted in Global News Feed
Comments Off on Mdxhealth to Present Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on February 26
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Posted: February 13, 2025 at 2:44 am
Media ReleaseCOPENHAGEN, Denmark; February 12, 2025
Read more from the original source:
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Posted in Global News Feed
Comments Off on Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Posted: February 13, 2025 at 2:44 am
ORION CORPORATION STOCK EXCHANGE RELEASE – MAJOR SHAREHOLDER ANNOUNCEMENTS12 FEBRUARY 2025 at 21.00 EET
Posted in Global News Feed
Comments Off on Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Posted: February 13, 2025 at 2:44 am
Study Progresses to Fourth Higher 90 mg/m2 Dose Cohort
Posted in Global News Feed
Comments Off on Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
Posted: February 13, 2025 at 2:44 am
– Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares
Read the original post:
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
Posted in Global News Feed
Comments Off on Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
Posted: February 13, 2025 at 2:44 am
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein
Continue reading here:
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
Posted in Global News Feed
Comments Off on Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Posted: February 13, 2025 at 2:44 am
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.
Follow this link:
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Posted in Global News Feed
Comments Off on Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Posted: February 13, 2025 at 2:44 am
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation
See the rest here:
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Posted in Global News Feed
Comments Off on Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for March 3, 2025 at 4:30 P.M. Eastern Time
Posted: February 13, 2025 at 2:44 am
GERMANTOWN, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2024 financial results after market close on Monday, March 3, 2025.
Posted in Global News Feed
Comments Off on Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for March 3, 2025 at 4:30 P.M. Eastern Time
